trial · primary record
Enzalutamide
Castration-Resistant Prostate Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 58 |
| Primary completion | 2026-05-07 |
| Primary endpoint | PSA Response, Defined by a PSA Decrease of at Least 50% Confirmed by a Second Measurement at Least 3 Weeks Later |
| Registry ID | NCT02312557 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:42:51.561Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02312557
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- ENZALUTAMIDE · approval
- Enzalutamide · compound